Logo image of ENZ

ENZO BIOCHEM INC (ENZ) Stock Fundamental Analysis

NYSE:ENZ - New York Stock Exchange, Inc. - US2941001024 - Common Stock - Currency: USD

0.5164  -0.01 (-2.07%)

Fundamental Rating

2

Overall ENZ gets a fundamental rating of 2 out of 10. We evaluated ENZ against 108 industry peers in the Health Care Providers & Services industry. The financial health of ENZ is average, but there are quite some concerns on its profitability. ENZ has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ENZ has reported negative net income.
In the past year ENZ has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ENZ reported negative net income in multiple years.
ENZ had negative operating cash flow in 4 of the past 5 years.
ENZ Yearly Net Income VS EBIT VS OCF VS FCFENZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

ENZ has a Return On Assets of -30.33%. This is amonst the worse of the industry: ENZ underperforms 84.11% of its industry peers.
ENZ has a worse Return On Equity (-47.92%) than 70.09% of its industry peers.
Industry RankSector Rank
ROA -30.33%
ROE -47.92%
ROIC N/A
ROA(3y)-12.64%
ROA(5y)-11.26%
ROE(3y)-18.05%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
ENZ Yearly ROA, ROE, ROICENZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

ENZ has a better Gross Margin (44.39%) than 71.96% of its industry peers.
In the last couple of years the Gross Margin of ENZ has grown nicely.
ENZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y9.93%
ENZ Yearly Profit, Operating, Gross MarginsENZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

5

2. Health

2.1 Basic Checks

ENZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ENZ has been increased compared to 1 year ago.
The number of shares outstanding for ENZ has been increased compared to 5 years ago.
The debt/assets ratio for ENZ has been reduced compared to a year ago.
ENZ Yearly Shares OutstandingENZ Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ENZ Yearly Total Debt VS Total AssetsENZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.34, we must say that ENZ is in the distress zone and has some risk of bankruptcy.
ENZ's Altman-Z score of -4.34 is on the low side compared to the rest of the industry. ENZ is outperformed by 85.98% of its industry peers.
ENZ has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ENZ has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. ENZ outperforms 84.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.34
ROIC/WACCN/A
WACC9.66%
ENZ Yearly LT Debt VS Equity VS FCFENZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 2.55 indicates that ENZ has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.55, ENZ belongs to the top of the industry, outperforming 81.31% of the companies in the same industry.
ENZ has a Quick Ratio of 2.28. This indicates that ENZ is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ENZ (2.28) is better than 79.44% of its industry peers.
Industry RankSector Rank
Current Ratio 2.55
Quick Ratio 2.28
ENZ Yearly Current Assets VS Current LiabilitesENZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ENZ have decreased strongly by -68.94% in the last year.
Looking at the last year, ENZ shows a very negative growth in Revenue. The Revenue has decreased by -57.49% in the last year.
Measured over the past years, ENZ shows a very negative growth in Revenue. The Revenue has been decreasing by -17.04% on average per year.
EPS 1Y (TTM)-68.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.02%
Revenue 1Y (TTM)-57.49%
Revenue growth 3Y-35.29%
Revenue growth 5Y-17.04%
Sales Q2Q%-20.41%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENZ Yearly Revenue VS EstimatesENZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ENZ Yearly EPS VS EstimatesENZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENZ. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENZ Price Earnings VS Forward Price EarningsENZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENZ Per share dataENZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 19.36%, ENZ is a good candidate for dividend investing.
The stock price of ENZ dropped by -46.76% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
ENZ's Dividend Yield is rather good when compared to the industry average which is at 3.01. ENZ pays more dividend than 100.00% of the companies in the same industry.
ENZ's Dividend Yield is rather good when compared to the S&P500 average which is at 2.27.
Industry RankSector Rank
Dividend Yield 19.36%

5.2 History

ENZ does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
ENZ Yearly Dividends per shareENZ Yearly Dividends per shareYearly Dividends per share 2024 0.02 0.04 0.06 0.08

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
ENZ Yearly Income VS Free CF VS DividendENZ Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

More info and screens

ENZO BIOCHEM INC

NYSE:ENZ (2/21/2025, 8:15:51 PM)

0.5164

-0.01 (-2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)12-11 2024-12-11/amc
Earnings (Next)03-17 2025-03-17
Inst Owners34.1%
Inst Owner Change-99.57%
Ins Owners10.57%
Ins Owner Change2.96%
Market Cap26.98M
Analysts80
Price TargetN/A
Short Float %0.73%
Short Ratio1.65
Dividend
Industry RankSector Rank
Dividend Yield 19.36%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.89
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.58
BVpS0.91
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.33%
ROE -47.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.39%
FCFM N/A
ROA(3y)-12.64%
ROA(5y)-11.26%
ROE(3y)-18.05%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y9.93%
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.94%
Cap/Sales 2.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.55
Quick Ratio 2.28
Altman-Z -4.34
F-Score3
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)89.52%
Cap/Depr(5y)102.77%
Cap/Sales(3y)7.08%
Cap/Sales(5y)5.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-68.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.02%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-57.49%
Revenue growth 3Y-35.29%
Revenue growth 5Y-17.04%
Sales Q2Q%-20.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y82.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.7%
OCF growth 3YN/A
OCF growth 5YN/A